Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation

Development of targeted therapies for squamous cell lung cancer (SqCLC) is currently limited by the prevalence of activating mutations and their predicting power of treatment efficacy. In the present study, we describe a case of treatment-naïve stage IIIB SqCLC that harbored a rare epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Weitao, Zhang, Chao, Tang, Yong, Tian, Dan, Lan, Zihua, Zeng, Cheng, Qiao, Guibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450156/
https://www.ncbi.nlm.nih.gov/pubmed/34552336
http://dx.doi.org/10.2147/OTT.S328839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450156/
https://www.ncbi.nlm.nih.gov/pubmed/34552336
http://dx.doi.org/10.2147/OTT.S328839

Ejemplares similares